Stahl D, Lacroix-Desmazes S, Sibrowski W, Kazatchkine M D, Kaveri S V
INSERM U430, Université Pierre et Marie Curie, Hôpital Broussais, Paris, France.
Leuk Lymphoma. 2001 Jun;42(1-2):163-76. doi: 10.3109/10428190109097688.
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by a malignant CD5+ B-cell clone. The leukemic clone commonly expresses IgM antibodies exhibiting reactivity toward a wide range of self-antigens. However, B-CLL associated autoimmunity is typically restricted to self-antigens expressed by blood cells, and mediated by IgG autoantibodies of polyclonal origin. In the present study, we addressed the question whether self-reactive antibody repertoires of plasma IgM and IgG are disturbed by monoclonal immunoglobulins of B-CLL patients, and whether antibody repertoires of patients exhibiting B-CLL associated target-restricted autoimmune disease (AID) differ from those of B-CLL patients without AID. We investigated antibody repertoires at a global level, using a technique of quantitative immunoblotting that allows for the quantitative screening of antibody reactivities in complex antibody mixtures toward a large panel of antigens derived from homologous tissue extracts, followed by multiparametric statistical analysis of the data. We demonstrate that self-reactive antibody repertoires of plasma IgM and IgG are broadly altered in patients with B-CLL, that alterations in self-reactive antibody repertoires are not restricted to B-CLL patients exhibiting AID, and that target-restricted autoimmunity in B-CLL patients is associated with altered antibody repertoires not restricted to the target organ. We conclude that monoclonal alterations of immunoglobulin production in B-CLL are associated with broad defects of self-reactive antibody repertoires. Our observations suggest that the application of therapeutic IVIg preparations might influence B-CLL by restoring normal self-reactive antibody repertoires in plasma.
B 细胞慢性淋巴细胞白血病(B-CLL)的特征是恶性 CD5+ B 细胞克隆。白血病克隆通常表达对多种自身抗原具有反应性的 IgM 抗体。然而,B-CLL 相关的自身免疫通常局限于血细胞表达的自身抗原,并由多克隆来源的 IgG 自身抗体介导。在本研究中,我们探讨了 B-CLL 患者的单克隆免疫球蛋白是否会干扰血浆 IgM 和 IgG 的自身反应性抗体库,以及表现出 B-CLL 相关的靶标限制性自身免疫疾病(AID)的患者的抗体库是否与无 AID 的 B-CLL 患者不同。我们使用定量免疫印迹技术在全球范围内研究抗体库,该技术允许对复杂抗体混合物中针对来自同源组织提取物的大量抗原的抗体反应性进行定量筛选,随后对数据进行多参数统计分析。我们证明,B-CLL 患者血浆 IgM 和 IgG 的自身反应性抗体库广泛改变,自身反应性抗体库的改变不限于表现出 AID 的 B-CLL 患者,并且 B-CLL 患者的靶标限制性自身免疫与不限于靶器官的抗体库改变相关。我们得出结论,B-CLL 中免疫球蛋白产生的单克隆改变与自身反应性抗体库的广泛缺陷有关。我们的观察结果表明,治疗性静脉注射免疫球蛋白制剂的应用可能通过恢复血浆中正常的自身反应性抗体库来影响 B-CLL。